Domov › Nemalicelični pljučni rak › Oklahoma › Oklahoma City
Klinične študije za Nemalicelični pljučni rak v Oklahoma City, OK
28 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v Oklahoma City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Vključevanje udeležencevFaza 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Vključevanje udeležencevFaza 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- University of Oklahoma, Oklahoma City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Vključevanje udeležencevFaza 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Vključevanje udeležencevFaza 3
- Local Institution - 0418, Oklahoma City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Vključevanje udeležencevFaza 3
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Vključevanje udeležencevFaza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Vključevanje udeležencevFaza 2/3
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of Oklahoma, Oklahoma City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Vključevanje udeležencevFaza 3
- Clinical Study Site, Oklahoma City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Vključevanje udeležencevFaza 1/2
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Vključevanje udeležencevFaza 1
- OU Health Stephenson Cancer Center, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Vključevanje udeležencevFaza 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Vključevanje udeležencevFaza 1/2
- University of Oklahoma - Health Sciences Center, Oklahoma City
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Vključevanje udeležencevFaza 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Vključevanje udeležencevOpazovalna študija
- Mercy Hospital - OKC, Oklahoma City
Study of XB010 in Subjects With Solid Tumors
Vključevanje udeležencevFaza 1
- Stephenson Cancer Center, Oklahoma City
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- OU Stephenson Cancer Center, Oklahoma City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Vključevanje udeležencevOpazovalna študija
- Mercy Hospital Oklahoma City, Oklahoma City
GEMINI-NSCLC: NSCLC Biomarker Study
Vključevanje udeležencevOpazovalna študija
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Vključevanje udeležencevFaza 1
- Dren Investigational Site, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
Vključevanje udeležencevFaza 1
- University of Oklahoma, Oklahoma City
Študije za Nemalicelični pljučni rak v drugih mestih
- Houston, TX145 študij
- New York City, NY121 študij
- Arlington, VA104 študij
- Nashville, TN97 študij
- Boston, MA90 študij
- Los Angeles, CA87 študij
- St. Louis, MO73 študij
- Chicago, IL61 študij
- Baltimore, MD60 študij
- San Antonio, TX59 študij
- Columbus, OH57 študij
- Washington, DC55 študij
Druge študije v Oklahoma City
- Rak jajčnikov28 študij
- Rak endometrija25 študij
- Kolorektalni rak22 študij
- Rak prostate21 študij
- Rak pljuč19 študij
- Rak dojke17 študij
- Metastatski rak16 študij
- Rak (vse vrste)14 študij
- Akutna mieločna levkemija14 študij
- Ploščatocelični karcinom glave in vratu13 študij
- Rak mehurja11 študij
- Rak trebušne slinavke11 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.